BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03482635 |
Recruitment Status :
Completed
First Posted : March 29, 2018
Last Update Posted : May 22, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This trial has two sequentially enrolling parts with different objectives. The primary objectives of this trial are
- to prove the concept of clinical activity of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments and to identify efficacious and safe dose regimens in Part 1 (Phase II)
- to confirm efficacy and safety of BI655130 (SPESOLIMAB) in patients with moderate-to-severely active ulcerative colitis who have failed previous biologic treatments in Part 2 (Phase III)
- To provide, along with induction study 1368-0018 and the run-in cohort of 1368-0020, the target population to be evaluated in study 1368-0020.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Colitis, Ulcerative | Drug: Spesolimab Drug: Placebo | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 98 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI655130 (SPESOLIMAB) Induction Therapy in Patients With Moderate-to-severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy |
Actual Study Start Date : | March 27, 2018 |
Actual Primary Completion Date : | May 18, 2020 |
Actual Study Completion Date : | May 18, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Group 1- Placebo Group |
Drug: Placebo
Solution for infusion |
Experimental: Group 2- Small Dose Group |
Drug: Spesolimab
Solution for infusion |
Experimental: Group 3- Medium Dose Group |
Drug: Spesolimab
Solution for infusion |
Experimental: Group 4 - High Dose Group |
Drug: Spesolimab
Solution for infusion |
- Proportion of patients with Clinical Remission [ Time Frame: Up to week 12 ]
- Part 1 and 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline [ Time Frame: Up to baseline and week 12 ]
- Part 1 and 2: Proportion of patients with combined Mucosal healing and histologic remission [ Time Frame: Up to week 12 ]
- Part 1: Proportion of patients with Mucosal Healing [ Time Frame: Up to week 12 ]
- Part 1: Proportion of patients with Clinical response [ Time Frame: Up to week 12 ]
- Part 2: Proportion of patients with Mucosal Healing [ Time Frame: Up to week 12 ]
- Part 2: Proportion of patients with Clinical response [ Time Frame: Up to week 12 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 - 75 years, at date of signing informed consent, males or females
- Diagnosis of ulcerative colitis ≥ 3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report
- Moderate to severe activity (total MCS 6 to 12 with a RBS ≥ 1 AND an SFS ≥ 1 AND mESS ≥ 2 within 7-28 days prior to first dose)
- Endoscopic activity extending proximal to the rectum (≥ 15 cm from anal verge)
- Well-documented demonstration of inadequate response or loss of response or have had unacceptable side effects with approved doses of TNFɑ antagonists (infliximab, adalimumab, golimumab) and/or vedolizumab in the past (screening of both TNFɑ antagonists-AND-Vedolizumab failure patients will be capped once 48 randomized patients in Part 1 and 117 randomized patients in Part 2 meet this criterion; patients who have already been screened at the time of the cap will continue to be randomized into the study)
- Further inclusion criteria apply
Exclusion Criteria:
- Evidence of abdominal abscess at screening
- Evidence of fulminant colitis or toxic megacolon at screening
- Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
- Further exclusion criteria apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03482635

Responsible Party: | Boehringer Ingelheim |
ClinicalTrials.gov Identifier: | NCT03482635 |
Other Study ID Numbers: |
1368-0005 2017-004230-28 ( EudraCT Number ) |
First Posted: | March 29, 2018 Key Record Dates |
Last Update Posted: | May 22, 2020 |
Last Verified: | May 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Colitis Colitis, Ulcerative Ulcer Gastroenteritis Gastrointestinal Diseases |
Digestive System Diseases Colonic Diseases Intestinal Diseases Pathologic Processes Inflammatory Bowel Diseases |